Literature DB >> 21383713

Reprogramming Rx.

Monya Baker.   

Abstract

Mesh：

Year:  2011        PMID： 21383713     DOI： 10.1038/nm0311-241

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  4 in total

1.  Direct conversion of human fibroblasts to multilineage blood progenitors.

Authors:  Eva Szabo; Shravanti Rampalli; Ruth M Risueño; Angelique Schnerch; Ryan Mitchell; Aline Fiebig-Comyn; Marilyne Levadoux-Martin; Mickie Bhatia
Journal:  Nature       Date:  2010-11-07       Impact factor: 49.962

2.  Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.

Authors:  Jakub Tolar; Lily Xia; Megan J Riddle; Chris J Lees; Cindy R Eide; Ron T McElmurry; Matthias Titeux; Mark J Osborn; Troy C Lund; Alain Hovnanian; John E Wagner; Bruce R Blazar
Journal:  J Invest Dermatol       Date:  2010-12-02       Impact factor: 8.551

3.  Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

4.  Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease.

Authors:  Marius Wernig; Jian-Ping Zhao; Jan Pruszak; Eva Hedlund; Dongdong Fu; Frank Soldner; Vania Broccoli; Martha Constantine-Paton; Ole Isacson; Rudolf Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205
  4 in total
  2 in total

Review 1.  The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.

Authors:  Zachary S Scheiner; Sohel Talib; Ellen G Feigal
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

2.  Mutations to the rescue.

Authors:  Mike May
Journal:  Nat Med       Date:  2011-04       Impact factor: 53.440
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.